Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated”  Off-the-Shelf Natural Killer Cell Therapy

14:12
 
Share
 

Manage episode 481375188 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

An Interview with:

Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA

CHICAGO – Several patients with acute myeloid leukemia, who were treated with SENTI-202, a first-in-class chimeric antigen receptor (CAR) natural killer (NK) cell therapy, experienced complete remission after not responding to (or having relapsed following) prior treatments, according to interim results from the phase one SENTI-202-101 clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research.

During the conference Audio Journal of Oncology correspondent Peter Goodwin met up with the lead author of the study, Stephen Strickland, Jr. MD MSCI, Director of Leukemia Research and Executive Chair of the Leukemia Research Committee at the Sarah Cannon Research Institute in Nashville, TN.

AACR Abstract title:

First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data

  continue reading

51 episodes

Artwork
iconShare
 
Manage episode 481375188 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

An Interview with:

Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA

CHICAGO – Several patients with acute myeloid leukemia, who were treated with SENTI-202, a first-in-class chimeric antigen receptor (CAR) natural killer (NK) cell therapy, experienced complete remission after not responding to (or having relapsed following) prior treatments, according to interim results from the phase one SENTI-202-101 clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research.

During the conference Audio Journal of Oncology correspondent Peter Goodwin met up with the lead author of the study, Stephen Strickland, Jr. MD MSCI, Director of Leukemia Research and Executive Chair of the Leukemia Research Committee at the Sarah Cannon Research Institute in Nashville, TN.

AACR Abstract title:

First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data

  continue reading

51 episodes

Kaikki jaksot

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play